Information Provided By: 
Fly News Breaks for March 6, 2018
FATE
Mar 6, 2018 | 05:20 EDT
Piper Jaffray analyst Edward Tenthoff doubled his price target for Fate Therapeutics to $20 and reiterates an Overweight rating on the shares following the company's Q4 results. Fate remains a 2018 top pick, Tenthoff tells investors in a post-earnings research note. Lead allogeneic natural killer cell therapy FATE-NK100 is in three ongoing Phase I studies and can enhance anti-tumor activity when combined with antibodies, the analyst contends.
News For FATE From the Last 2 Days
FATE
Apr 18, 2024 | 17:52 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSMetropolitan... To see the rest of the story go to thefly.com. See Story Here
